Mochi Health's combined membership-plus-medication structure commonly totals more per month than a flat-rate compounded provider charging for medication and care together.
Luma Health's compounded semaglutide ($197/month) and tirzepatide ($297/month) are priced as one flat number — no separate membership fee to add on top.
When patients compare "cheapest GLP-1 provider" options, Mochi Health often comes up because of its recognizable brand and app-based model. But comparing Mochi fairly against a flat-rate provider requires looking at the full monthly total, not just the headline medication price.
How Mochi Health's Pricing Is Structured
Mochi Health's model separates a membership fee (commonly reported around $79/month) from the medication cost itself, which is billed on top. Combined, patients have reported total monthly costs in the range of roughly $175-$230+/month depending on the specific medication and dose. It's worth confirming the current membership fee and medication pricing directly, since both can change.
How a Flat-Rate Model Compares
A flat-rate compounded provider folds the medical evaluation, provider access, and medication into a single number, with no separate membership layer. Luma Health's $197/month semaglutide and $297/month tirzepatide are priced this way — the number you see is the number you pay, regardless of dose level, with no membership fee added separately.
The most common mistake when comparing "cheapest" providers is comparing a membership fee against an all-inclusive price, or vice versa. Before deciding, add up everything you'd actually pay each month at your expected dose — membership plus medication plus any add-on fees — for a true side-by-side comparison.
What You're Getting for Mochi's Membership Fee
Mochi Health's app-based model includes provider messaging, dose management, and account tools accessible through its mobile app, which some patients specifically value for the interface and convenience. If that app experience is genuinely important to you, it's a real factor to weigh against the cost difference — not every patient's priorities are purely about the lowest total price.
Which Model Fits You
- Specifically value its app-based interface and experience
- Aren't primarily optimizing for the lowest possible monthly total
- Are comfortable with a membership-plus-medication billing structure
- Want the simplest possible monthly total to budget around
- Don't need a specific app experience to feel supported
- Want pricing that doesn't change as your dose increases
One number.
No membership fee added on top.
Compounded semaglutide at $197/month or tirzepatide at $297/month — medical evaluation, provider visits, and shipping all included.
Get Started → Or start your free health assessmentFrequently Asked Questions
Yes, according to publicly reported information, Mochi Health charges a membership fee (commonly around $79/month) separately from the medication cost itself.
Combined totals have been reported in the roughly $175-$230+/month range depending on medication and dose. Always verify current specific pricing directly with Mochi before enrolling.
A flat-rate provider like Luma Health folds everything into one number ($197/month semaglutide, $297/month tirzepatide) with no separate membership fee, which can be lower than a combined membership-plus-medication total.
No, when both prescribe compounded semaglutide or tirzepatide, the active ingredient and clinical mechanism are the same regardless of which platform prescribes it. What differs is pricing structure and support model.
Your full expected monthly total at your target dose, including any membership fees, not just the advertised starting medication price.
That depends on your personal priorities. If the app experience genuinely adds value for you, it may justify a higher total cost; if not, a flat-rate provider without that layer may be the more efficient choice.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov